ERBB2 and breast cancer: HER3 has been shown to be the most potent HER2/HER3 activator of the downstream PI3K/AKT pathway, and HER3 overexpression has been associated with trastuzumab resistance, suggesting that HER3 plays an oncogenic driver role in breast cancer [63].